PolyPid (NASDAQ:PYPD – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23), Zacks reports.
PolyPid Stock Performance
Shares of NASDAQ PYPD traded up $0.02 during midday trading on Wednesday, reaching $2.91. 5,177 shares of the company traded hands, compared to its average volume of 22,431. The company has a market cap of $29.64 million, a price-to-earnings ratio of -0.37 and a beta of 1.32. The stock has a 50-day moving average price of $3.02 and a 200 day moving average price of $3.32. PolyPid has a 52 week low of $2.37 and a 52 week high of $7.00. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.00 and a quick ratio of 1.00.
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on the company. Craig Hallum started coverage on PolyPid in a research report on Monday, November 4th. They issued a “buy” rating and a $10.00 target price on the stock. RODMAN&RENSHAW raised shares of PolyPid to a “strong-buy” rating in a report on Tuesday, January 28th. HC Wainwright reduced their target price on shares of PolyPid from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday, December 26th. Finally, Rodman & Renshaw began coverage on shares of PolyPid in a research report on Tuesday, January 28th. They issued a “buy” rating and a $13.00 target price for the company.
PolyPid Company Profile
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Featured Articles
- Five stocks we like better than PolyPid
- About the Markup Calculator
- Inflation Persists, But So Do Stock Opportunities: Rally On
- Business Services Stocks Investing
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
- How to Choose Top Rated Stocks
- Shopify Confirms Stock Uptrend, New Highs in Sight
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.
